DSK Legal Advised OneSource Specialty Pharma On Listing Of Equity Shares
DSK Legal Advised OneSource Specialty Pharma On Listing Of Equity Shares
DSK Legal advised and assisted OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited) (“the Company”) in connection with the filing of the Information Memorandum pursuant to a scheme of arrangement among Strides Pharma Science Limited, Steriscience Specialties Private Limited, and the Company (“the Scheme”) for the listing of 11,44,36,021 equity shares of ₹1 each.
The Company is a fully integrated, multi-modality specialty pharmaceutical contract development and manufacturing organization focused on drug-device combinations, biologics, sterile injectables, and oral technologies such as soft gelatin capsules. The Scheme was sanctioned by the NCLT, Mumbai, on November 14, 2024, and the Information Memorandum was filed with BSE and NSE on January 21, 2025. The Company’s equity shares were listed on BSE and NSE on January 24, 2025.
DSK Legal assisted the Company in:
(i) conducting diligence and drafting of the Information Memorandum;
(ii) drafting of all board resolutions and shareholder resolutions;
(iii) drafting and commenting on the standard certificates, auditor certificates and advertisements; and
(iv) reviewing and commenting on SEBI applications.
The deal team at DSK Legal included Avinash Poojari (Associate Partner), Akanksha Dubey (Principal Associate), and Sachi Ray (Associate). Anand Desai (Managing Partner) acted as the engagement and relationship partner.
